ReviewInfectious diseases and therapy2023
Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy.
Review in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- A macrophage-mimetic nanocarrier co-loaded with geraniol and FK13-a1 for MRSA-induced acute lung injury.Drug delivery · 2026Article
- Observational
- Antimicrobial Resistance and Comparative Genome Analysis of High-RiskMicroorganisms · 2026Article
- Tracheostomy and Ventilator-Associated Pneumonia in Mechanically Ventilated ICU Patients: A Retrospective Matched Cohort Study.Journal of clinical medicine · 2026Article
- Genotypic and phenotypic landscape of carbapenem-resistant Pseudomonas aeruginosa isolated from respiratory and non-respiratory samples in a tertiary hospital.BMC microbiology · 2026Article
- Unveiling Antibiotic Resistance in Ventilator-Associated Pneumonia Patients: A Comprehensive Analysis.Cureus · 2026Article
- Genetic Determinants Linked to MDR/XDR inPathogens (Basel, Switzerland) · 2026Article
- Genotypic and phenotypic characterization of Pseudomonas aeruginosa PAV112: a virulent clinical strain causing severe pneumonia and lethal sepsis in a murine infection model.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Antimicrobial resistance in ICU endotracheal aspirates: Evidence to support stewardship in Bangladesh.Bioinformation · 2026Article
- Impact of ddPCR panel implementation on optimizing antimicrobial therapy management in critically ill patients with bloodstream infections.Frontiers in cellular and infection microbiology · 2026Article
- Whole genome sequencing of ceftolozane/tazobactam-resistant, XDRFrontiers in cellular and infection microbiology · 2026Article
- Comparative effectiveness of intravenous versus inhalational antibiotic administration for the management of Acinetobacter pneumonia: A randomized controlled trial.Qatar medical journal · 2026Article
- Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2026Review
- Precision metagenomics reveals microbial landscape in acute upper respiratory infections: a comprehensive dataset.BMC research notes · 2025Article
- Corticosteroids and hospital-acquired pneumonia.Pneumonia (Nathan Qld.) · 2025Review
- Resistance Dynamics in a Romanian Critical Care Unit: Four Years of ESKAPE Pathogen Surveillance.Medicina (Kaunas, Lithuania) · 2025Observational
- Prevalence of Healthcare-Acquired Infections Among Adults in Intensive Care Units: A Systematic Review and Meta-Analysis.Health science reports · 2025Review
- Nebulized Antibiotics for Preventing and Treating Gram-Negative Respiratory Infections in Critically Ill Patients: An Overview of Reviews.Antibiotics (Basel, Switzerland) · 2025Review
- Enhanced prediction of ventilator-associated pneumonia in patients with traumatic brain injury using advanced machine learning techniques.Scientific reports · 2025Article
- Detecting Respiratory Pathogens for Diagnosing Lower Respiratory Tract Infections at the Point of Care: Challenges and Opportunities.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventilator-associated pneumonia (VAP) is a serious intensive care unit (ICU)-related infection in mechanically ventilated patients that is frequent, as more than half of antibiotics prescriptions in ICU are due to VAP. Various risk factors and diagnostic criteria for VAP have been referred to in different settings. The estimated attributable mortality of VAP can go up to 50%, which is higher in cases of antimicrobial-resistant VAP. When the diagnosis of pneumonia in a mechanically ventilated patient is made, initiation of effective antimicrobial therapy must be prompt. Microbiological diagnosis of VAP is required to optimize timely therapy since effective early treatment is fundamental for better outcomes, with controversy continuing regarding optimal sampling and testing. Understanding the role of antimicrobial resistance in the context of VAP is crucial in the era of continuously evolving antimicrobial-resistant clones that represent an urgent threat to global health. This review is focused on the risk factors for antimicrobial resistance in adult VAP and its novel microbiological tools. It aims to summarize the current evidence-based knowledge about the mechanisms of resistance in VAP caused by multidrug-resistant bacteria in clinical settings with focus on Gram-negative pathogens. It highlights the evidence-based antimicrobial management and prevention of drug-resistant VAP. It also addresses emerging concepts related to predictive microbiology in VAP and sheds lights on VAP in the context of coronavirus disease 2019 (COVID-19).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.